StemRIM (TSE:4599) Debt-to-Revenue : N/A (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is StemRIM Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

StemRIM's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. StemRIM's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. StemRIM's annualized Revenue for the quarter that ended in Jan. 2024 was 円0 Mil.

StemRIM Debt-to-Revenue Historical Data

The historical data trend for StemRIM's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Debt-to-Revenue Chart

StemRIM Annual Data

Trend

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Debt-to-Revenue

Get a 7-Day Free Trial

0.13

0.01

0.16

StemRIM Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	-	N/A	N/A	N/A

Competitive Comparison of StemRIM's Debt-to-Revenue

For the Biotechnology subindustry, StemRIM's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StemRIM's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where StemRIM's Debt-to-Revenue falls into.

StemRIM Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

StemRIM's Debt-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.531	+	0)	/	2350
	=	0.00

StemRIM's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jan. 2024) Revenue data.

StemRIM Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of StemRIM's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

StemRIM (TSE:4599) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085

Website

https://www.stemrim.com

StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM (TSE:4599) Headlines

No Headlines